McKaylee M Robertson1,2, Kate Penrose3, Mary K Irvine3, Rebekkah S Robbins3, Sarah Kulkarni1,2, Sarah L Braunstein3, Levi Waldron1,2, Graham Harriman3, Denis Nash1,2. 1. Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York City, New York. 2. Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York City, New York. 3. New York City Department of Health and Mental Hygiene, Bureau of HIV/AIDS Prevention and Control, New York City, New York.
Abstract
BACKGROUND: To assess long-term effectiveness of an intensive and comprehensive Ryan White Part A-funded HIV Care Coordination Program recruiting people living with HIV with a history of suboptimal HIV care outcomes. METHODS: We merged programmatic data on CCP clients with surveillance data on all adults diagnosed with HIV. Using propensity score matching, we identified a contemporaneous, non-CCP-exposed comparison group. Durable viral suppression (DVS) was defined as regular viral load (VL) monitoring and all VLs ≤200 copies per milliliter in months 13-36 of follow-up. RESULTS: Ninety percent of the combined cohort (N = 12,414) had ≥1 VL ≤200 during the follow-up period (December 1, 2009-March 31, 2016), and nearly all had routine VL monitoring, but only 36.8% had DVS. Although DVS did not differ overall (relative risk: 0.99, 95% confidence interval: 0.95 to 1.03), CCP clients without any VL suppression (VLS) in the 12-month pre-enrollment showed higher DVS versus "usual care" recipients (21.3% versus 18.4%; relative risk: 1.16, 95% confidence interval: 1.04 to 1.29). CONCLUSIONS: Enrollment in an intensive intervention modestly improved DVS among those unsuppressed before CCP enrollment. This program shows promise for meeting treatment-as-prevention goals and advancing progress along the HIV care continuum, if people without evidence of VLS are prioritized for CCP enrollment over those with recent evidence of VLS. Low overall DVS (<40%) levels underscore a need for focused adherence maintenance interventions, in a context of high treatment access.
BACKGROUND: To assess long-term effectiveness of an intensive and comprehensive Ryan White Part A-funded HIV Care Coordination Program recruiting people living with HIV with a history of suboptimal HIV care outcomes. METHODS: We merged programmatic data on CCP clients with surveillance data on all adults diagnosed with HIV. Using propensity score matching, we identified a contemporaneous, non-CCP-exposed comparison group. Durable viral suppression (DVS) was defined as regular viral load (VL) monitoring and all VLs ≤200 copies per milliliter in months 13-36 of follow-up. RESULTS: Ninety percent of the combined cohort (N = 12,414) had ≥1 VL ≤200 during the follow-up period (December 1, 2009-March 31, 2016), and nearly all had routine VL monitoring, but only 36.8% had DVS. Although DVS did not differ overall (relative risk: 0.99, 95% confidence interval: 0.95 to 1.03), CCP clients without any VL suppression (VLS) in the 12-month pre-enrollment showed higher DVS versus "usual care" recipients (21.3% versus 18.4%; relative risk: 1.16, 95% confidence interval: 1.04 to 1.29). CONCLUSIONS: Enrollment in an intensive intervention modestly improved DVS among those unsuppressed before CCP enrollment. This program shows promise for meeting treatment-as-prevention goals and advancing progress along the HIV care continuum, if people without evidence of VLS are prioritized for CCP enrollment over those with recent evidence of VLS. Low overall DVS (<40%) levels underscore a need for focused adherence maintenance interventions, in a context of high treatment access.
Authors: Julia C Dombrowski; Susan E Buskin; Amy Bennett; Hanne Thiede; Matthew R Golden Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Mary K Irvine; Stephanie A Chamberlin; Rebekkah S Robbins; Sarah G Kulkarni; McKaylee M Robertson; Denis Nash Journal: AIDS Behav Date: 2017-06
Authors: Qiang Xia; Sarah L Braunstein; Ellen W Wiewel; Joanna J Eavey; Colin W Shepard; Lucia V Torian Journal: J Acquir Immune Defic Syndr Date: 2016-08-15 Impact factor: 3.731
Authors: Mary K Irvine; Stephanie A Chamberlin; Rebekkah S Robbins; Julie E Myers; Sarah L Braunstein; Beau J Mitts; Graham A Harriman; Fabienne Laraque; Denis Nash Journal: Clin Infect Dis Date: 2014-10-09 Impact factor: 9.079
Authors: Julia C Dombrowski; Mary Irvine; Denis Nash; Graham Harriman; Matthew R Golden Journal: J Acquir Immune Defic Syndr Date: 2019-12 Impact factor: 3.731
Authors: McKaylee M Robertson; Kate Penrose; Denis Nash; Graham Harriman; Sarah L Braunstein; Bruce Levin; Mary K Irvine Journal: AIDS Behav Date: 2020-04
Authors: Darren L Whitfield; LaRon E Nelson; Arnošt Komárek; DeAnne Turner; Zhao Ni; Donte T Boyd; Tamara Taggart; S Raquel Ramos; Leo Wilton; Geetha G Beauchamp; Lisa Hightow-Weidman; Steven J Shoptaw; Manya Magnus; Kenneth H Mayer; Sheldon D Fields; Darrell P Wheeler Journal: J Racial Ethn Health Disparities Date: 2022-01-08
Authors: Elliott R Weinstein; Audrey Harkness; Gail Ironson; Cho-Hee Shrader; Dustin T Duncan; Steven A Safren Journal: Int J Behav Med Date: 2022-05-02
Authors: Michael J Li; Erica Su; Wendy H Garland; Sona Oksuzyan; Sung-Jae Lee; Uyen H Kao; Robert E Weiss; Steven J Shoptaw Journal: J Acquir Immune Defic Syndr Date: 2020-08-01 Impact factor: 3.771
Authors: Mary K Irvine; Bruce Levin; McKaylee M Robertson; Katherine Penrose; Jennifer Carmona; Graham Harriman; Sarah L Braunstein; Denis Nash Journal: BMJ Open Date: 2020-07-27 Impact factor: 2.692
Authors: Elizabeth R Stevens; Kimberly A Nucifora; Mary K Irvine; Katherine Penrose; McKaylee Robertson; Sarah Kulkarni; Rebekkah Robbins; Bisrat Abraham; Denis Nash; R Scott Braithwaite Journal: PLoS One Date: 2019-04-25 Impact factor: 3.240
Authors: Julia C Dombrowski; Sean R Galagan; Meena Ramchandani; Shireesha Dhanireddy; Robert D Harrington; Allison Moore; Katie Hara; Mckenna Eastment; Matthew R Golden Journal: Open Forum Infect Dis Date: 2019-06-26 Impact factor: 3.835
Authors: Karen Diepstra; Haidong Lu; Kathleen A McManus; Elizabeth T Rogawski McQuade; Anne G Rhodes; Daniel Westreich Journal: AIDS Date: 2020-09-01 Impact factor: 4.632